Inconex Xl

Tolterodine, the active ingredient in Inconex Xl, is an antimuscarinic (anticholinergic) presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency, and urge urinary incontinence in adults.

GNH USA supplies Inconex Xl as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inconex Xl, an antimuscarinic agent, is used to manage conditions related to overactive bladder and urinary urgency. - Overactive bladder: reduces involuntary bladder contractions to improve storage capacity. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daily voids. - Urge urinary incontinence: helps prevent involuntary leakage.

Tolterodine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Constipation: slowed gastrointestinal motility. - Blurred vision: transient visual disturbances. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. - Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects: - Allergic reactions: rash, pruritus, or angioedema. - Severe constipation: risk of bowel obstruction. - Acute urinary retention: may require catheterisation. - Tachycardia: rapid heart rate. - QT interval prolongation: potential cardiac arrhythmia.

Before prescribing Inconex Xl, clinicians should consider several safety aspects. - Assess renal function: adjust use in severe impairment. - Monitor for urinary retention: especially in patients with prostate enlargement. - Avoid in uncontrolled narrow‑angle glaucoma: anticholinergic effect may worsen condition. - Use caution in the elderly: increased anticholinergic burden. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Tolterodine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise tolterodine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may lower effectiveness. - Other anticholinergic agents: additive anticholinergic effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may increase risk of urinary retention. - Beta‑agonists: could diminish therapeutic benefit. - Alcohol: may enhance dizziness and sedation.